VWF antibody (AA 1815-1939)
Quick Overview for VWF antibody (AA 1815-1939) (ABIN6251948)
Target
See all VWF AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 1815-1939
-
Purification
- Protein G affinity chromatography
-
Immunogen
- Amino acids 1815-1939 from the human protein were used as the immunogen for this vWF antibody.
-
Isotype
- IgG2b kappa
-
-
-
-
Application Notes
-
Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT
The optimal dilution of the vWF antibody for each application should be determined by the researcher. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- PBS with 0.1 mg/mL BSA and 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot and Store at -20C. Avoid freez-thaw cycles.
-
-
- VWF (Von Willebrand Factor (VWF))
-
Alternative Name
- von Willebrand Factor / vWF
-
Background
- Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.
-
Gene ID
- 7450
-
UniProt
- P04275
Target
-